Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Cellular and Molecular Biology 58: Oncogenes

Ras pathway activation in mesothelioma

Manish R. Patel, Blake A. Jacobson, Faris Farassati and Robert A. Kratzke
Manish R. Patel
University of Minnesota Medical Center, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Blake A. Jacobson
University of Minnesota Medical Center, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Faris Farassati
University of Minnesota Medical Center, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert A. Kratzke
University of Minnesota Medical Center, Minneapolis, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2006
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 47, 2006

Abstract

4231

The critical molecular pathways involved in growth and proliferation of malignant pleural mesothelioma (MPM) are largely unknown. Although Ras mutations are uncommon in MPM, silencing of the RASSF1A (a Ras inhibitor) has been described in MPM. Furthermore, the downstream targets of the Ras pathway have not been elucidated in this malignancy. Here we sought to determine the activation status of Ras in MPM cell lines and its downstream effectors in MPM. Furthermore, we studied the potential role of Ras pathway activation on the control of the cellular translational machinery in MPM. Methods: LP9 normal mesothelial cells and human mesothelioma cell lines 2373, 2461, and 2596 were grown in RPMI growth medium supplemented with 10% calf serum to 70% confluence. Cell lysates were prepared and protein concentrations were determined using the Bradford assay. The Ras activation affinity pull-down assay was used to evaluate the amount of Ras-GTP (activated Ras) in 2373, 2461, 2596 in comparison to LP9 cells. Kinase activity of downstream Ras effectors was determined by assessing phosphorylation of related substrates such as Elk-1. Furthermore, crude lysates of MPM cell lines as well as LP9 were subjected to Western analysis for assessing the levels of regulators of translational control, eIF4E, 4EBP-1, and eIF4G. Results: High levels of Ras activation, as determined by the presence of Ras-GTP, was identified in 2 of 3 MPM cell lines compared to LP9 normal mesothelial cells. Furthermore, phosphorylation of Elk-1 by Erk42/44 was greater in all 3 MPM cell lines compared to LP9 cells. Total levels of eIF4E and eIF4G were not different between MPM cell lines and LP9 cells. However, 4EBP-1 was present in its hyper-phosphorylated form in 2 out of 3 MPM cell lines compared to LP9 cells. Conclusions: Ras and its downstream effectors are activated in MPM. One potential downstream target of the Ras pathway is the controlling elements of cap-dependent translation. Therefore, manipulation of such a signaling network via gene therapy or pharmacological methods might play a role in treatment of MPM.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 66 (8 Supplement)
April 2006
Volume 66, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Ras pathway activation in mesothelioma
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Ras pathway activation in mesothelioma
Manish R. Patel, Blake A. Jacobson, Faris Farassati and Robert A. Kratzke
Cancer Res April 15 2006 (66) (8 Supplement) 995;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Ras pathway activation in mesothelioma
Manish R. Patel, Blake A. Jacobson, Faris Farassati and Robert A. Kratzke
Cancer Res April 15 2006 (66) (8 Supplement) 995;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • MDM2 prevents cyclin A expression and S phase progression of normal cells through a pathway regulated by cyclin dependent kinase inhibitor p16: a property overcome by cancer cells
  • Overexpression of the novel oncoprotein gankyrin in human esophageal squamous cell carcinoma (ESCC) and its clinical significance
  • Akt1 and 2 mediate malignant progression in GBM, Akt3 has tumor suppressor-like function
Show more Cellular and Molecular Biology 58: Oncogenes
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement